clinically relevant deterioration of motion behavior does not occur during sustained rivastigmine application in AD patients. From this point of view rivastigmine is also suitable for the treatment of PD patients with dementia. Disclosures The author has no conﬂicts of interest to disclose. References Alva G, Potkin SG. 2003. Alzheimer disease and other dementias. Clin Geriatr Med, 19:763–76. Belle SH, Zhang S, Czaja SJ, et al. 2004. Use of cognitive enhancement medication in persons with Alzheimer disease who have a family caregiver: results from the Resources for Enhancing Alzheimer’s Caregiver Health (REACH) project. Am J Geriatr Psychiatry, 12:250–7. Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer’s disease. Lancet, 368:387–403. Blount PJ, Nguyen CD, McDeavitt JT. 2002. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil, 17:314–21. Bohnen N, Kaufer D, Hendrickson R, et al. 2004. Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol, 24:354–6. Bonner LT, Peskind ER. 2002. Pharmacologic treatments of dementia. Med Clin North Am, 86:657–74. Bullock R, Touchon J, Bergman H, et al. 2005. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin, 21:1317–27. Clegg A, Bryant J, Nicholson T, et al. 2002. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease. A systematic review. Int J Technol Assess Health Care, 18:497–507. Corey-Bloom J, Anand R, Veach J; for the ENA 713 B352 Study. 1998. A randomized trial evaluating the efﬁcacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol, 1:55–65. Cummings JL. 2000. Cholinesterase inhibitors: expanding applications. Lancet, 356:2024–5. Cummings JL. 2005. Behavioral and neuropsychiatric outcomes in Alzheimer’s disease. CNS Spectr, 10(Suppl 18):22–5. Darreh-Shori T, Almkvist O, Guan ZZ, et al. 2002. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology, 594:563–72. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, et al. 2004. Long- lasting acetylcholinesterase splice variations in anticholinesterase- treated Alzheimer’s disease patients. J Neurochem, 885:1102–13. Darvesh S, Hopkins DA, Geula C. 2003. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci, 4:131–8. Di Lazzaro V, Oliviero A, Pilato F, et al. 2004. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 75:555–9. Emre M. 2004. Dementia in Parkinson’s disease:cause and treatment. Curr Opin Neurol, 174:399–404. Erkinjuntti T, Skoog I, Lane R, et al. 2002. Rivastigmine in patients with Alzheim- er’s disease and concurrent hypertension. Int J Clin Pract, 5610:791–6. Eskander MF, Nagykery NG, Leung EY, et al. 2005. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res, 1060:144–52. Factor SA, Friedman JH, Lannon MC, et al. 2001. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease:results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord, 16:135–9. Rivastigmine in AD Farlow M, Anand R, Messina J Jr, et al. 2000. A 52-week study of the efﬁcacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol, 44:236–41. Farlow M, Potkin S, Koumaras B, et al. 2003. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol, 60:843–8. Farlow MR. 2002. Do cholinesterase inhibitors slow progression of Alzheimer’s disease? Int J Clin Pract, (Suppl):37–44. Farlow MR, Hake A, Messina J, et al. 2001. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol, 58:417–22. Farlow MR, Lilly ML. 2005. Rivastigmine:an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatr, 5:3. Forette F, Anand R, Gharabawi G. 1999. A phase II study in patients with Alzheimer’s disease to assess the preliminary efﬁcacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol, 6:423–9. Frankfort SV, Appels BA, de Boer A, et al. 2005. Discontinuation of rivastigmine in routine clinical practice. Int J Geriatr Psychiatry, 20:1167–71. Frankfort SV, Appels BA, de Boer A, et al. 2006. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer’s disease in an outpatient geriatric setting. Int J Clin Pract, 60:646–54. Giacobini E. 2000. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann NY Acad Sci, 920:321–7. Giladi N, Shabtai H, Gurevich T, et al. 2003. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand, 108:368–73. Gill SS, Bronskill SE, Mamdani M, et al. 2004. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol, 11:e274–e85. Greig NH, Lahiri DK, Sambamurti K. 2002. Butyrylcholinesterase:an important new target in Alzheimer’s disease therapy. Int Psychogeriatr, 14(Suppl 1):77–91. Hegerl U, Mergl R, Henkel V, et al. 2003. Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol, 23:214–16. Heinze M, Andreae D, Grohmann R. 2002. Rivastigmin and impaired motor function. Pharmacopsychiatry, 35:79–80. Ioffe ME. 2004. Brain mechanisms for the formation of new movements during learning:the evolution of classical concepts. Neurosci Behav Physiol, 34:5–18. Jefferson AL, Cosentino SA, Ball SK, et al. 2002. Errors produced on the mini-mental state examination and neuropsychological test performance in Alzheimer’s disease, ischemic vascular dementia, and Parkinson’s disease. J Neuropsychiatry Clin Neurosci, 14:311–20. Juncos JL, Roberts VJ, Evatt ML, et al. 2004. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov Disord, 19:29–35. Kurz A, Farlow M, Quarg P, et al. 2004. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord, 18:123–8. Leroi I, Brandt J, Reich SG, et al. 2004. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry, 19:1–8. Liepert J, Bar KJ, Meske U, et al. 2001. Motor cortex disinhibition in Alzheimer’s disease. Clin Neurophysiol, 112:1436–41. Matheson AJ, Lamb HM. 2000. Quetiapine–A review of its clinical potential in the management of psychotic symptoms in Parkinson’s disease. CNS Drugs, 14:157–72. Merims D, Shabtai H, Korczyn AD, et al. 2004. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm, 111:1447–53. Neuropsychiatric Disease and Treatment 2007:3(2) 217